BOOSTRIX 2 UNIT / 0.5 ML — DIN 02247600
DIPHTHERIA TOXOID : 2 UNIT / 0.5 ML PERTUSSIS TOXOID : 8 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 8 MCG / 0.5 ML TETANUS TOXOID : 20 UNIT / 0.5 ML PERTACTIN : 2.5 MCG / 0.5 ML · GLAXOSMITHKLINE INC · SUSPENSION · wholesale supply in Canada
Health Canada status: MARKETED
What is BOOSTRIX?
BOOSTRIX 2 UNIT / 0.5 ML contains DIPHTHERIA TOXOID : 2 UNIT / 0.5 ML PERTUSSIS TOXOID : 8 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 8 MCG / 0.5 ML TETANUS TOXOID : 20 UNIT / 0.5 ML PERTACTIN : 2.5 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02247600, held by GLAXOSMITHKLINE INC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 29-May-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BOOSTRIX used for?
BOOSTRIX (combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine) is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards, and for passive protection against pertussis in early infancy following maternal immunisation during pregnancy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Other Bacterial Vaccines in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Other Bacterial Vaccines, across 4 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GLAXOSMITHKLINE INC | 2 | 1 | BOOSTRIX, LYMERIX | Sourceable in Canada |
| HOLLISTER-STIER LABORATORIES LLC | 1 | 0 | MRV | No marketed DIN |
| OMEGA LABORATORIES LIMITED | 1 | 0 | MEGAVAC INJ | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 UNIT / 0.5 ML |
|---|---|
| Dosage form | SUSPENSION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | prefilled syringes (type I glass) with a plunger stopper (butyl rubber) and with a rubber tip cap (in packages of 10). |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Other Bacterial Vaccines |
|---|---|
| ATC code | J07AX |
| AHFS class | 80:08.00 ; 80:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02247600 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2247600 |
| Brand name | BOOSTRIX |
| Generic / active ingredient | DIPHTHERIA TOXOID : 2 UNIT / 0.5 ML PERTUSSIS TOXOID : 8 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 8 MCG / 0.5 ML TETANUS TOXOID : 20 UNIT / 0.5 ML PERTACTIN : 2.5 MCG / 0.5 ML |
| Market authorization holder | GLAXOSMITHKLINE INC |
| Health Canada schedule | Schedule D |
| ATC code | J07AX |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J07AX |
| Current status | MARKETED |
| Status date | 29-May-2007 |
| Original market date | 2007-05-29 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Single 0.5 mL dose by deep intramuscular injection. Not for primary immunization. Booster intervals generally every 10 years. Can be given during third trimester of pregnancy.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to components; encephalopathy within 7 days of previous pertussis vaccine; transient thrombocytopenia or neurological complications after previous diphtheria/tetanus vaccination.
Warnings and precautions
Not for IV use. Postpone in acute severe febrile illness. Potential risk of Guillain-Barré Syndrome or brachial neuritis. Caution in individuals with bleeding disorders/thrombocytopenia.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| LYMERIX | 30 MCG / 0.5 ML | LIQUID | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | 02239195 |
| MEGAVAC INJ | 75 M | LIQUID | OMEGA LABORATORIES LIMITED | CANCELLED POST MARKET | 00316393 |
| MRV | 200 M | SUSPENSION | HOLLISTER-STIER LABORATORIES LLC | CANCELLED POST MARKET | 02216981 |
2 · Same class — other molecules in ATC J07AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Other Bacterial Vaccines | BOOSTRIX · LYMERIX · MEGAVAC INJ · MRV | 4 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J07A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J07AH | Meningococcal Vaccines · Meningococcus B, Multicomponent Vaccine · Meningococcus C, Purified Polysaccharides Antigen Conjugated · Meningococcus, A, C, Bivalent Purified Polysacc. Antigen · Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen · +1 more | 17 | 6 |
| J07AL | Pneumococcus, Purified Polysacc.antigen Conjugated · Pneumococcus, Purified Polysaccharides Antigen | 11 | 3 |
| J07AE | Cholera, Inactivated, Whole Cell · Cholera, Live Attenuated | 4 | 2 |
| J07AP | Typhoid, Inactivated, Whole Cell · Typhoid, Oral, Live Attenuated · Typhoid, Purified Polysaccharide Antigen | 5 | 2 |
| J07AJ | Pertussis, Inact., Whole Cell, Comb. With Toxoids · Pertussis, Inactivated, Whole Cell · Pertussis, Purified Antigen · Pertussis, Purified Antigen, Comb. With Toxoids | 7 | 1 |
| J07AM | Tetanus Toxoid · Tetanus Toxoid, Comb. With Diphtheria Toxoid | 7 | 1 |
| J07AG | Hemophilus Influenzae B Vaccines · Hemophilus Influenzae B, Combinations With Pertussis And Toxoids · Hemophilus Influenzae B, Combinations With Toxoids · Hemophilus Influenzae B, Purified Antig. Conjugated | 8 | 1 |
| J07AF | Diphtheria Toxoid | 4 | 0 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADACEL | PERTUSSIS TOXOID : 2.5 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 5 MCG / 0.5 ML DIPHTHERIA TOXOID : 2 LF / 0.5 ML PERTACTIN : 3 MCG / 0.5 ML FIMBRIAE TYPES 2 AND 3 (FIM) : 5 MCG / 0.5 ML TETANUS TOXOID : 5 LF / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02240255 |
| DUKORAL | VIBRIO CHOLERAE INABA 48 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE INABA 6973 EL TOR BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS RECOMBINANT CHOLERA TOXIN B SUBUNIT : 1 MG | VALNEVA SWEDEN AB | MARKETED | 02247208 |
| VAXCHORA | VIBRIO CHOLERAE, STRAIN CVD 103-HGR, LIVE : 2000000000 UNIT | BAVARIAN NORDIC AS | MARKETED | 02538164 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.